Stevanato Group S.p.A. (NYSE: STVN) saw its stock surge 5.8% in the pre-market session on Friday, driven by strong Q4 2024 financial results, progress in expanding manufacturing capacity, and positive guidance for the upcoming year.
In its Q4 2024 earnings call, the company reported a 2% revenue growth for the full year 2024, with a 6% increase in the Biopharmaceutical and Diagnostic Solutions segment. Notably, revenue from injectable biologics grew by 24% year-over-year, indicating strong demand in this high-growth segment.
Stevanato Group achieved significant milestones during the year, with its Fishers, Indiana facility generating its first commercial revenue and the Latina project in Italy turning profitable at the gross profit margin level. The company is strategically investing in expanding its manufacturing capacity for high-value products, such as syringes and cartridges, to meet the growing demand for biologic treatments and self-administrative medicines.
Looking ahead, Stevanato Group provided positive guidance for 2025, forecasting revenue between €1.160 billion and €1.190 billion, adjusted EBITDA in the range of €293 million to €306.3 million, and adjusted diluted EPS ranging from €0.51 to €0.55. The company expects sequential growth in revenue and margins throughout the year, driven by the ramp-up of new manufacturing lines and a gradual recovery in vial demand.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。